Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Cancer Treatment Reviews|June 29, 2021
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?Federica Giugliano, Edoardo Crimini, Paolo Tarantino, et al.
NPJ Breast Cancer|January 30, 2025
Understanding metastasis mixed-treatment responses through genomic analysesSusana Garcia-Recio, Paola Zagami, Brooke M Felsheim, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2019
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trialFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Chirurgia (Bucharest, Romania : 1990)|December 30, 2021
Systemic Treatment of Ductal Carcinoma In Situ of the BreastEdoardo Crimini, Chiara Corti, Matteo Repetto, et al.
La Radiologia Medica|January 22, 2026
Can the new combined CEUS-BI-RADS score (CB score) reduce the number of breast false positive biopsies? Results from a monocentric studyAntonio Portaluri, Renato Trimarchi, Xin Wang, et al.
JAMA Network Open|December 20, 2023
Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast CancerPaola Zagami, Aranzazu Fernandez-Martinez, Naim U Rashid, et al.
Breast (Edinburgh, Scotland)|January 18, 2025
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancerPaola Zagami, Angela Esposito, Beatrice Taurelli Salimbeni, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2023
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastasesPamela Trillo, Josè Sandoval, Dario Trapani, et al.
Expert Opinion on Pharmacotherapy|May 22, 2026
Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title: oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancerJulian David Etessami, Carmine Valenza, Pier Paolo Maria Berton Giachetti, et al.
JCO Oncology Practice|October 1, 2024
Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerSabah Alaklabi, Arya Mariam Roy, Paola Zagami, et al.
Pageof 6